Industry

Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial Two new indications bring AstraZeneca and Daiichi Sankyo’s ENHERTU into curative-intent setting, reinforcing its role across stages of HER2-positive breast cancer WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved … [Read more…]

Approved for use before surgery based on DESTINY-Breast11 phase 3 trial or following surgery based on DESTINY-Breast05 phase 3 trial Two new indications bring Daiichi Sankyo and AstraZeneca’s Enhertu into curative-intent setting, reinforcing its role across stages of HER2 positive breast cancer Enhertu now approved for nine indications with six across both early and metastatic … [Read more…]

TORRANCE, Calif.–(BUSINESS WIRE)–Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. Highlights “We realized an 18% decline in net revenues for three month ended … [Read more…]

First approved ctDNA MRD-guided therapy reinforcing Genentech’s commitment to innovation and practice-changing precision medicine New treatment approach enables healthcare professionals to tailor treatment with the goal of improving clinical benefit and reducing unnecessary intervention Approval marks the eleventh indication for Tecentriq in the U.S., providing a new option for an aggressive form of cancer SOUTH … [Read more…]

FORT MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis Investor 1×1 meetings on Thursday, May 28th The Jefferies Global Healthcare Conference 2026 in New York Fireside chat … [Read more…]

NEW DEHLI–(BUSINESS WIRE)–#Kitsault–Best Cure Foundation (BCF) and Kitsault Energy (KE), led by President/Founder Dr. Krishnan Suthanthiran, will host two press conferences this month in India, presenting comprehensive solutions addressing the nation’s energy, environmental, healthcare, and lifestyle challenges. The first press conference will be Tuesday, May 19, 2026, at the New Delhi National Press Club in … [Read more…]

Established sites join Iterative Health’s elite site network, expanding the company’s cardiovascular research capabilities CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the acquisition of three cardiology sites from NextStage Clinical Research with Bourne Partners serving as exclusive financial advisor on the transaction. Located across … [Read more…]

MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2026 results on Thursday, May 21, 2026, before markets open. A conference call and webcast to discuss the results will be held on Thursday, May 21, 2026, at 8:30am ET. To view, … [Read more…]

TORONTO–(BUSINESS WIRE)–OBIO® and Intellectual Property Ontario (IPON) have renewed their memorandum of understanding (MOU) to ensure that Ontario’s next generation of companies developing innovative human health products continue to access optimal intellectual property (IP) protection and commercialization support. Through this agreement, OBIO® and IPON will continue to jointly assist Ontario’s early-stage life sciences and health … [Read more…]

LONDON & NEW YORK–(BUSINESS WIRE)–$CMPS #Biotech–Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET. A … [Read more…]